Loading...
33 exercise COVID-19 controlled studies
https://c19early.com/exmeta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Hamer 28%
0.72 [0.61-0.87]
hosp.
n/a
n/a
Improvement, RR [CI] Treatment Control Hamer 34%
0.66 [0.55-0.79]
hosp.
n/a
n/a
Brawner 74%
0.26 [0.11-0.58]
hosp.
n/a
n/a
Zhang 26%
0.74 [0.48-1.14]
death
n/a
n/a
Zhang 18%
0.82 [0.69-0.96]
cases
n/a
n/a
Tavakol 69%
0.31 [0.10-1.02]
severe case
3/64
19/124
Yates 45%
0.55 [0.38-0.79]
death
72/163,912
62/30,119
Yates 47%
0.53 [0.43-0.66]
severe case
291/163,912
180/30,119
Holt 17%
0.83 [0.63-1.09]
cases
n/a
n/a
Cho 53%
0.47 [0.26-0.87]
death
case control
Cho 10%
0.90 [0.86-0.95]
cases
case control
Sallis 59%
0.41 [0.22-0.76]
death
11/3,118
170/6,984
Sallis 42%
0.58 [0.40-0.85]
ICU
32/3,118
195/6,984
Sallis 53%
0.47 [0.38-0.58]
hosp.
99/3,118
732/6,984
Christensen 63%
0.37 [0.16-0.85]
death
543 (n)
529 (n)
Christensen 23%
0.77 [0.52-1.15]
cases
55/543
77/529
Latorre-Román 76%
0.24 [0.05-1.04]
hosp.
n/a
n/a
Latorre-Román 87%
0.13 [0.01-1.17]
hosp.
n/a
n/a
Marcus 42%
0.58 [0.48-0.71]
symp. case
240/10,627
134/3,708
Yuan 91%
0.09 [0.01-1.65]
death
0/61
6/103
Yuan 70%
0.30 [0.09-0.92]
severe case
3/61
26/103
Brandenburg -6%
1.06 [0.23-4.79]
hosp.
102 (n)
39 (n)
Brandenburg 78%
0.22 [0.05-1.02]
hosp.
177 (n)
34 (n)
Brandenburg 64%
0.36 [0.13-0.98]
hosp.
97 (n)
34 (n)
Brandenburg 35%
0.65 [0.28-1.48]
severe case
102 (n)
39 (n)
Brandenburg 24%
0.76 [0.28-2.04]
severe case
52 (n)
34 (n)
Bielik 30%
0.70 [0.40-1.21]
mod. case
775 (n)
365 (n)
Bielik -9%
1.09 [0.69-1.73]
cases
775 (n)
365 (n)
Lee 74%
0.26 [0.07-0.99]
death
2/11,072
32/41,293
Lee 58%
0.42 [0.19-0.91]
severe case
39/11,072
273/41,293
Lee 16%
0.84 [0.73-0.98]
cases
291/11,072
1,293/41,293
Maltagliati 52%
0.48 [0.25-0.87]
hosp.
n/a
n/a
Baynouna AlKetbi 98%
0.01 [0.00-0.44]
death
n/a
n/a
Ahmadi 30%
0.70 [0.54-0.89]
death
160/232,613
112/95,221
Nguyen 20%
0.80 [0.72-0.88]
symp. case
904/2,836
483/1,111
Lin 47%
0.53 [0.12-2.33]
cases
n/a
n/a
de Souza 73%
0.27 [0.07-1.06]
ventilation
3/611
6/327
de Souza 34%
0.66 [0.43-0.99]
hosp.
49/611
42/327
Mohsin 19%
0.81 [0.66-0.99]
severe case
86/258
224/544
Mohsin -1%
1.01 [0.88-1.15]
severe case
290/698
224/544
Ekblom-Bak 48%
0.52 [0.30-0.92]
severe case
n/a
n/a
Lengelé 74%
0.26 [0.07-0.80]
cases
23/229
4/12
Saadeh 9%
0.91 [0.56-1.43]
symp. case
362 (n)
225 (n)
Saadeh 4%
0.96 [0.62-1.43]
symp. case
362 (n)
225 (n)
Hamrouni 29%
0.71 [0.55-0.92]
death
138/106,006
109/47,827
Huang 47%
0.53 [0.23-1.22]
severe case
7/74
16/90
Huang 8%
0.92 [0.30-2.85]
severe case
3/23
20/141
Huang 66%
0.34 [0.17-0.70]
cases
n/a
n/a
Steenkamp 42%
0.58 [0.50-0.68]
death
29,469 (n)
13,366 (n)
Steenkamp 45%
0.55 [0.47-0.64]
ventilation
29,469 (n)
13,366 (n)
Steenkamp 41%
0.59 [0.52-0.66]
ICU
29,469 (n)
13,366 (n)
Gilley -42%
1.42 [0.60-3.35]
cases
172/1,917
5/79
Beydoun 43%
0.57 [0.32-1.01]
cases
1,710 (n)
448 (n)
Beydoun 62%
0.38 [0.18-0.78]
cases
672 (n)
448 (n)
Salgado-Aranda 83%
0.17 [0.05-0.56]
death
4/223
41/297
Paul 38%
0.62 [0.30-1.20]
no recov.
n/a
n/a
Paul 4%
0.96 [0.53-1.63]
no recov.
n/a
n/a
Kontopoulou 66%
0.34 [0.24-0.47]
recov. time
42 (n)
24 (n)
Kontopoulou 67%
0.33 [0.24-0.46]
no recov.
42 (n)
24 (n)
exercise COVID-19 outcomes c19early.com/ex May 2022
Favors exercise
Favors inactivity
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation.
FLCCC and
WCH
provide treatment protocols.
Submit
